At a glance
ClinicalIndex Comparison RecordN/ACompleted· 24 enrolled
Drug / intervention
Adalimumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Observational Study to Assess Quality of Life Changes in Swedish Patients With Moderate or Severe Hidradenitis Suppurativa (HS) After 6 Months on Adalimumab Treatment (HOPE Study)
In Brief
An observational study evaluating Adalimumab for Hidradenitis Suppurativa. Completed, enrolled 24 participants across 11 sites.
Detailed Summary
The objective of this study is to assess quality of life (QoL), skin pain, work productivity/activity and health related problems in Swedish patients with moderate to severe HS before and after 6 months treatment with Adalimumab. Participants will be treated in accordance with normal routine clinical care.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesSweden
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2016
First PostedApr 2016
Primary CompletionMar 2018
TodayJul 2026
First PostedApr 15, 2016
Enrollment StartApr 7, 2016
Primary CompletionMar 28, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.2 years ago
Interventions
Adalimumabbiological
Adalimumab